Diabetes Compounds Vascular Damage by Disrupting Critical Cell Signaling Pathway
The most important finding of this study is that diabetes-induced TREM2-endothelial cell signaling impairs ischemic vascular repair, suggesting a potential therapeutic target for diabetic patients with peripheral arterial disease (PAD) [1].
Diabetes mellitus (DM) is a chronic condition that affects millions of people worldwide, and its impact on cardiovascular health is well-documented. Individuals with diabetes are at a higher risk of developing vascular diseases, including peripheral arterial disease (PAD), which can lead to severe complications such as limb amputation and even death. The underlying mechanisms of diabetic vasculopathy are complex and involve multiple cell types, including endothelial cells (ECs) and macrophages (Mφs). These cells play a crucial role in maintaining vascular homeostasis, and their dysfunction in diabetes contributes to the development of vascular diseases.
The relationship between diabetes and vascular disease is bidirectional, with diabetes accelerating vascular disease and vascular disease exacerbating diabetes. The exact mechanisms by which diabetes disrupts vascular function are not fully understood, but it is clear that the interaction between ECs and Mφs is critical. Single-cell profiling has revealed the heterogeneity of ECs and Mφs, but how this diversity translates into cell-cell interactions and vascular function remains unclear. Recent studies have highlighted the importance of understanding the crosstalk between ECs and Mφs in the context of diabetic vasculopathy.
The study of diabetic vasculopathy is an active area of research, with scientists working to identify key molecular players and signaling pathways that contribute to the development of vascular diseases in diabetes. The identification of these players and pathways is crucial for the development of effective therapeutic strategies to prevent or treat diabetic vasculopathy. By elucidating the mechanisms of diabetic vasculopathy, researchers hope to uncover potential targets for intervention, ultimately improving the outcomes of diabetic patients with vascular diseases.
The researchers in this study used single-cell RNA sequencing and spatial transcriptomics to profile human mesenteric arteries from non-diabetic donors and from donors with type 2 diabetes (T2D) [1]. They generated a transcriptome and interactome atlas of diabetic vasculature, which identified triggering receptor expressed on myeloid cells 2 (TREM2) as one of the top T2D-induced genes in mononuclear phagocytes (MPs). TREM2+ MPs exhibited foam cell-like features but acquired a proinflammatory gene profile in DM. The study also found that TREM2 inhibition in vitro attenuated proinflammatory responses in MPs and ECs and enhanced EC migration.
The researchers further investigated the role of TREM2 in diabetic vasculopathy using streptozotocin- and high-fat high-sucrose diet-induced mouse models of diabetes with hindlimb ischemia, a model of PAD [1]. They found that TREM2 blockade using a neutralizing antibody improved perfusion recovery, whereas TREM2 activation with an agonist exacerbated ischemic injury. Analysis of clinical samples confirmed elevated EC-TREM2 signaling in human PAD, particularly in the setting of DM, highlighting its translational relevance. These findings suggest that TREM2-EC interaction may be a driver of diabetic vasculopathy and a potential therapeutic target in DM-associated PAD.
The clinical implications of this study are significant, as they suggest that targeting TREM2-EC signaling may be a promising therapeutic strategy for diabetic patients with PAD [1]. This is particularly important, as current treatment options for PAD are limited, and new approaches are urgently needed. The study's findings also highlight the importance of considering the complex interplay between ECs and Mφs in the development of diabetic vasculopathy. By understanding the molecular mechanisms underlying this interplay, researchers may be able to develop more effective treatments for diabetic patients with vascular diseases.
The study used a combination of single-cell RNA sequencing, spatial transcriptomics, and in vitro and in vivo models to investigate the role of TREM2-EC signaling in diabetic vasculopathy [1]. The researchers analyzed human mesenteric arteries from non-diabetic donors and from donors with T2D, and used mouse models of diabetes with hindlimb ischemia to investigate the effects of TREM2 blockade and activation on perfusion recovery and ischemic injury.
The findings of this study have important implications for patients with diabetes and vascular disease [1]. While the study's results are promising, it is essential to note that more research is needed to fully understand the role of TREM2-EC signaling in diabetic vasculopathy. Readers should consult their healthcare provider to discuss their individual risk factors and treatment options. Additionally, individuals with diabetes can take steps to reduce their risk of vascular disease by maintaining good blood sugar control, exercising regularly, and following a healthy diet. By understanding the complex mechanisms underlying diabetic vasculopathy, researchers and clinicians may be able to develop more effective treatments and improve outcomes for patients with these devastating diseases.
